Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around

Description

Summary

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors

Official Title

First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors

Keywords

Advanced Solid Tumor, Neoplasms, AMT-116

Eligibility

Locations

  • University of California San Francisco Cancer Center not yet accepting patients
    San Francisco 94115 American Samoa
  • Sarah Cannon Research Institute not yet accepting patients
    Denver Colorado 80218 United States
  • Mary Crowley Cancer Research Centers accepting new patients
    Dallas Texas 75230 United States
  • Carolina BioOncology Institute, LLC accepting new patients
    Cary 28078 American Samoa

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Multitude Therapeutics Inc.
ID
NCT05725291
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 80 study participants
Last Updated